NYLIM
YMAB

New York Life Investment Management’s Y-mAbs Therapeutics YMAB Stock Holding History

New York Life Investment Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-68,932
Closed -$470K – 1546
2023
Q4 		$470K Sell
68,932
-2,023
-3% -$11.7K ﹤0.01% 874
2023
Q3 		$387K Sell
70,955
-11,307
-14% -$65.8K ﹤0.01% 916
2023
Q2 		$559K Sell
82,262
-63,546
-44% -$476K 0.01% 662
2023
Q1 		$730K Buy
+145,808
New +$595K 0.01% 626

Other funds holding YMAB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

New York Life Investment Management's YMAB Position: Q1 2024 in Review

New York Life Investment Management sold out of Y-mAbs Therapeutics (YMAB) in Q1 2024, closing a stake of 68,932 shares — an estimated $470K sold.

New York Life Investment Management first reported a position in YMAB in Q1 2023 and held it in 4 quarters. The position peaked at $730K in Q1 2023. 96 funds tracked by Wall St. Rank hold YMAB as of Q1 2024.

  • New York Life Investment Management reported no remaining Y-mAbs Therapeutics position as of Q1 2024 after selling out during the quarter.
  • New York Life Investment Management sold 68,932 Y-mAbs Therapeutics shares in Q1 2024, an estimated $470K.
  • New York Life Investment Management first reported a position in Y-mAbs Therapeutics in Q1 2023 and held it in 4 quarters.
  • New York Life Investment Management's Y-mAbs Therapeutics position peaked at $730K in Q1 2023.
  • 96 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2024.

Based on New York Life Investment Management's 13F filing for Q1 2024, filed 6 May 2024.